Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 368

1.

Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.

Merz M, Hielscher T, Schult D, Mai EK, Raab MS, Hillengass J, Seckinger A, Hose D, Granzow M, Jauch A, Goldschmidt H.

Leukemia. 2019 Nov 11. doi: 10.1038/s41375-019-0634-2. [Epub ahead of print] No abstract available.

PMID:
31712777
2.

GTPase-activating protein Rasal1 associates with ZAP-70 of the TCR and negatively regulates T-cell tumor immunity.

Thaker YR, Raab M, Strebhardt K, Rudd CE.

Nat Commun. 2019 Oct 22;10(1):4804. doi: 10.1038/s41467-019-12544-4.

3.

Influence of transcutaneous vagus nerve stimulation on cardiac vagal activity: Not different from sham stimulation and no effect of stimulation intensity.

Borges U, Laborde S, Raab M.

PLoS One. 2019 Oct 11;14(10):e0223848. doi: 10.1371/journal.pone.0223848. eCollection 2019.

4.

IKZF1/3 and CRL4-CRBN E3 ubiquitin ligase mutations and IMiD resistance in multiple myeloma.

Barrio S, Munawar U, Zhu YX, Giesen N, Shi CX, Da Viá M, Sanchez R, Bruins L, Demler T, Müller N, Haertle L, Garitano A, Steinbrunn T, Danhof S, Cuenca I, Barrio-Garcia C, Braggio E, Rosenwald A, Martinez-Lopez J, Rasche L, Raab MS, Stewart AK, Einsele H, Stühmer T, Kortüm KM.

Haematologica. 2019 Sep 26. pii: haematol.2019.217943. doi: 10.3324/haematol.2019.217943. [Epub ahead of print]

5.

Creative and Intuitive Decision-Making Processes: A Comparison of Brazilian and German Soccer Coaches and Players.

Klatt S, Noël B, Musculus L, Werner K, Laborde S, Lopes MC, Greco PJ, Memmert D, Raab M.

Res Q Exerc Sport. 2019 Dec;90(4):651-665. doi: 10.1080/02701367.2019.1642994. Epub 2019 Sep 3.

PMID:
31478798
6.

FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas.

Brand F, Förster A, Christians A, Bucher M, Thomé CM, Raab MS, Westphal M, Pietsch T, von Deimling A, Reifenberger G, Claus P, Hentschel B, Weller M, Weber RG.

Acta Neuropathol. 2020 Jan;139(1):175-192. doi: 10.1007/s00401-019-02067-z. Epub 2019 Aug 31.

PMID:
31473790
7.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.

Merz M, Hielscher T, Mai EK, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Dürig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J.

Blood Cancer J. 2019 Aug 27;9(9):71. doi: 10.1038/s41408-019-0235-3. No abstract available.

8.

Embodied Cognition With and Without Mental Representations: The Case of Embodied Choices in Sports.

Raab M, Araújo D.

Front Psychol. 2019 Aug 7;10:1825. doi: 10.3389/fpsyg.2019.01825. eCollection 2019. Review.

9.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S.

N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.

PMID:
31433920
10.

Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.

Baertsch MA, Lutz R, Raab MS, Weinhold N, Goldschmidt H.

J Cancer Res Clin Oncol. 2019 Oct;145(10):2445-2455. doi: 10.1007/s00432-019-02998-w. Epub 2019 Aug 12.

PMID:
31407112
11.

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.

Hájek R, Delforge M, Raab MS, Schoen P, DeCosta L, Spicka I, Radocha J, Pour L, Gonzalez-McQuire S, Bouwmeester W.

Br J Haematol. 2019 Nov;187(4):447-458. doi: 10.1111/bjh.16105. Epub 2019 Aug 6.

12.

Immune adaptor SKAP1 acts a scaffold for Polo-like kinase 1 (PLK1) for the optimal cell cycling of T-cells.

Raab M, Strebhardt K, Rudd CE.

Sci Rep. 2019 Jul 18;9(1):10462. doi: 10.1038/s41598-019-45627-9.

13.

Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.

Raab M, Kobayashi NF, Becker S, Kurunci-Csacsko E, Krämer A, Strebhardt K, Sanhaji M.

Int J Cancer. 2020 Feb 15;146(4):1086-1098. doi: 10.1002/ijc.32559. Epub 2019 Jul 22.

PMID:
31286496
14.

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.

Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A.

J Hematol Oncol. 2019 Jun 26;12(1):65. doi: 10.1186/s13045-019-0750-5.

15.

Editorial: The Psychophysiology of Action.

Hoffmann S, Beste C, Raab M.

Front Psychol. 2019 May 31;10:1266. doi: 10.3389/fpsyg.2019.01266. eCollection 2019. No abstract available.

16.

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau IW, Raab MS, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann HW, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Haenel M, Scheid C, Goldschmidt H.

BMC Cancer. 2019 May 28;19(1):504. doi: 10.1186/s12885-019-5600-x.

17.

Quantitative analysis of the sHLA-G protein in seminal plasma.

Schallmoser A, Raab M, Karn T, Königsberger S, Schmidt E, Breitenbach-Koller H, Sänger N.

Am J Reprod Immunol. 2019 Sep;82(3):e13152. doi: 10.1111/aji.13152. Epub 2019 Jun 10.

PMID:
31132194
18.

Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.

Mohty M, Cavo M, Fink L, Gonzalez-McQuire S, Leleu H, Mateos MV, Raab MS, Schoen P, Yong K.

Eur J Haematol. 2019 Aug;103(2):107-115. doi: 10.1111/ejh.13264. Epub 2019 Jun 18.

19.

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma.

Raab MS, Thomas SK, Ocio EM, Guenther A, Goh YT, Talpaz M, Hohmann N, Zhao S, Xiang F, Simon C, Vanasse KG, Kumar SK.

Leukemia. 2019 Dec;33(12):2924-2933. doi: 10.1038/s41375-019-0482-0. Epub 2019 May 15.

PMID:
31092894
20.

Doubly resonant sum frequency spectroscopy of mixed photochromic isomers on surfaces reveals conformation-specific vibronic effects.

Raab M, Becca JC, Heo J, Lim CK, Baev A, Jensen L, Prasad PN, Velarde L.

J Chem Phys. 2019 Mar 21;150(11):114704. doi: 10.1063/1.5081726.

PMID:
30902002
21.

[Erratum to: First-line treatment of multiple myeloma].

Breitkreutz I, Raab M, Goldschmidt H.

Internist (Berl). 2019 May;60(5):552. doi: 10.1007/s00108-019-0581-z. German. No abstract available.

PMID:
30887073
22.

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma.

Rasche L, Kortüm KM, Raab MS, Weinhold N.

Int J Mol Sci. 2019 Mar 12;20(5). pii: E1248. doi: 10.3390/ijms20051248. Review.

23.

Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.

Raab M, Sanhaji M, Zhou S, Rödel F, El-Balat A, Becker S, Strebhardt K.

Neoplasia. 2019 Apr;21(4):363-375. doi: 10.1016/j.neo.2019.01.007. Epub 2019 Mar 7.

24.

Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity.

Watts E, Heidenreich D, Tucker E, Raab M, Strebhardt K, Chesler L, Knapp S, Bellenie B, Hoelder S.

J Med Chem. 2019 Mar 14;62(5):2618-2637. doi: 10.1021/acs.jmedchem.8b01947. Epub 2019 Feb 21.

25.

Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma.

Sachpekidis C, Merz M, Kopp-Schneider A, Jauch A, Raab MS, Sauer S, Hillengass J, Goldschmidt H, Dimitrakopoulou-Strauss A.

Haematologica. 2019 Sep;104(9):e420-e423. doi: 10.3324/haematol.2018.213041. Epub 2019 Feb 14. No abstract available.

26.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.

Kriegsmann K, Baertsch MA, Awwad MHS, Merz M, Hose D, Seckinger A, Jauch A, Becker N, Benner A, Raab MS, Hillengass J, Bertsch U, Dürig J, Salwender HJ, Hänel M, Fenk R, Munder M, Weisel K, Müller-Tidow C, Goldschmidt H, Hundemer M.

Blood Cancer J. 2019 Jan 29;9(2):13. doi: 10.1038/s41408-019-0174-z.

27.

Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.

Campa D, Martino A, Macauda A, Dudziński M, Suska A, Druzd-Sitek A, Raab MS, Moreno V, Huhn S, Butrym A, Sainz J, Szombath G, Rymko M, Marques H, Lesueur F, Vangsted AJ, Vogel U, Kruszewski M, Subocz E, Buda G, Iskierka-Jażdżewska E, Ríos R, Merz M, Schöttker B, Mazur G, Perrial E, Martinez-Lopez J, Butterbach K, García Sanz R, Goldschmidt H, Brenner H, Jamroziak K, Reis RM, Kadar K, Dumontet C, Wątek M, Haastrup EK, Helbig G, Jurczyszyn A, Jerez A, Varkonyi J, Barington T, Grzasko N, Zaucha JM, Andersen V, Zawirska D, Canzian F.

Leuk Lymphoma. 2019 Jul;60(7):1803-1811. doi: 10.1080/10428194.2018.1551536. Epub 2019 Jan 11.

PMID:
30633655
28.

Interrelations Between Temporal and Spatial Cognition: The Role of Modality-Specific Processing.

Loeffler J, Cañal-Bruland R, Schroeger A, Tolentino-Castro JW, Raab M.

Front Psychol. 2018 Dec 21;9:2609. doi: 10.3389/fpsyg.2018.02609. eCollection 2018. Review.

29.

A developmental perspective on option generation and selection.

Musculus L, Ruggeri A, Raab M, Lobinger B.

Dev Psychol. 2019 Apr;55(4):745-753. doi: 10.1037/dev0000665. Epub 2018 Dec 20.

PMID:
30570294
30.

[First-line treatment of multiple myeloma].

Breitkreutz I, Raab M, Goldschmidt H.

Internist (Berl). 2019 Jan;60(1):23-33. doi: 10.1007/s00108-018-0527-x. Review. German. Erratum in: Internist (Berl). 2019 May;60(5):552.

PMID:
30552458
31.

The role of PLK1 in cancer exhibiting chromosomal instability.

Strebhardt K, Raab M, Sanhaji M.

Mol Cell Oncol. 2018 Sep 20;5(6):e1485539. doi: 10.1080/23723556.2018.1485539. eCollection 2018.

32.

Immune adaptor protein SKAP1 (SKAP-55) forms homodimers as mediated by the N-terminal region.

Raab M, Strebhardt K, Rudd CE.

BMC Res Notes. 2018 Dec 6;11(1):869. doi: 10.1186/s13104-018-3976-3.

33.

Can the use of digital algorithms improve quality care? An example from Afghanistan.

Bernasconi A, Crabbé F, Raab M, Rossi R.

PLoS One. 2018 Nov 26;13(11):e0207233. doi: 10.1371/journal.pone.0207233. eCollection 2018.

34.

Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.

Raab MS, Fink L, Schoen P, Gonzalez-McQuire S, Flinois A, Cavo M, Mateos MV, Yong K.

Br J Haematol. 2019 Jun;185(5):981-984. doi: 10.1111/bjh.15680. Epub 2018 Nov 22. No abstract available.

PMID:
30467828
35.

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J.

N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.

PMID:
30403938
36.

Erratum: Persistence-Driven Durotaxis: Generic, Directed Motility in Rigidity Gradients [Phys. Rev. Lett. 118, 078103 (2017)].

Novikova EA, Raab M, Discher DE, Storm C.

Phys Rev Lett. 2018 Oct 12;121(15):159901. doi: 10.1103/PhysRevLett.121.159901.

PMID:
30362797
37.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO.

Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.

38.

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.

Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, Bertsch U, Munder M, Weisel K, Salwender HJ, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M.

Oncoimmunology. 2018 Aug 1;7(10):e1486356. doi: 10.1080/2162402X.2018.1486356. eCollection 2018.

39.

The Power of Shape: How Shape of Node-Link Diagrams Impacts Aesthetic Appreciation and Triggers Interest.

Carbon CC, Mchedlidze T, Raab MH, Wächter H.

Iperception. 2018 Sep 8;9(5):2041669518796851. doi: 10.1177/2041669518796851. eCollection 2018 Sep-Oct.

40.

The Psychophysiology of Action: A Multidisciplinary Endeavor for Integrating Action and Cognition.

Hoffmann S, Borges U, Bröker L, Laborde S, Liepelt R, Lobinger BH, Löffler J, Musculus L, Raab M.

Front Psychol. 2018 Aug 29;9:1423. doi: 10.3389/fpsyg.2018.01423. eCollection 2018.

41.

Towards structural biology with super-resolution microscopy.

Molle J, Jakob L, Bohlen J, Raab M, Tinnefeld P, Grohmann D.

Nanoscale. 2018 Sep 13;10(35):16416-16424. doi: 10.1039/c8nr03361g.

PMID:
30141803
42.

IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells.

Plaumann J, Engelhardt M, Awwad MHS, Echchannaoui H, Amman E, Raab MS, Hillengass J, Halama N, Neuber B, Müller-Tidow C, Goldschmidt H, Hundemer M.

Cancer Immunol Immunother. 2018 Nov;67(11):1695-1707. doi: 10.1007/s00262-018-2230-0. Epub 2018 Aug 20.

PMID:
30128739
43.

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.

Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, Hundemer M, Jauch A, Hegenbart U, Raab MS, Ho AD, Schönland S, Hose D.

Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018.

44.

Spectrum and functional validation of PSMB5 mutations in multiple myeloma.

Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortüm KM.

Leukemia. 2019 Feb;33(2):447-456. doi: 10.1038/s41375-018-0216-8. Epub 2018 Jul 19.

PMID:
30026573
45.

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Merz M, Hielscher T, Hoffmann K, Seckinger A, Hose D, Raab MS, Hillengass J, Jauch A, Goldschmidt H.

Leukemia. 2018 Dec;32(12):2717-2719. doi: 10.1038/s41375-018-0202-1. Epub 2018 Jul 6. No abstract available.

PMID:
29977018
46.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G.

Leukemia. 2019 Jan;33(1):159-170. doi: 10.1038/s41375-018-0196-8. Epub 2018 Jul 2.

47.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29. No abstract available.

PMID:
29959413
48.

LINC complex-Lis1 interplay controls MT1-MMP matrix digest-on-demand response for confined tumor cell migration.

Infante E, Castagnino A, Ferrari R, Monteiro P, Agüera-González S, Paul-Gilloteaux P, Domingues MJ, Maiuri P, Raab M, Shanahan CM, Baffet A, Piel M, Gomes ER, Chavrier P.

Nat Commun. 2018 Jun 22;9(1):2443. doi: 10.1038/s41467-018-04865-7.

49.

Psychodiagnostics: Classification of the Yips Phenomenon based on Musician's Dystonia.

Ioannou CI, Klämpfl MK, Lobinger BH, Raab M, Altenmüller E.

Med Sci Sports Exerc. 2018 Nov;50(11):2217-2225. doi: 10.1249/MSS.0000000000001696.

PMID:
29933350
50.

Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.

Raab M, Sanhaji M, Pietsch L, Béquignon I, Herbrand AK, Süß E, Gande SL, Caspar B, Kudlinzki D, Saxena K, Sreeramulu S, Schwalbe H, Strebhardt K, Biondi RM.

ACS Chem Biol. 2018 Aug 17;13(8):1921-1931. doi: 10.1021/acschembio.7b01078. Epub 2018 Jun 28.

PMID:
29927572

Supplemental Content

Support Center